Kelli Glenn

1.8k total citations · 1 hit paper
20 papers, 1.4k citations indexed

About

Kelli Glenn is a scholar working on Oncology, Molecular Biology and Psychiatry and Mental health. According to data from OpenAlex, Kelli Glenn has authored 20 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Molecular Biology and 7 papers in Psychiatry and Mental health. Recurrent topics in Kelli Glenn's work include Epilepsy research and treatment (7 papers), Cancer-related Molecular Pathways (7 papers) and Neuroscience and Neuropharmacology Research (5 papers). Kelli Glenn is often cited by papers focused on Epilepsy research and treatment (7 papers), Cancer-related Molecular Pathways (7 papers) and Neuroscience and Neuropharmacology Research (5 papers). Kelli Glenn collaborates with scholars based in United States, Switzerland and South Korea. Kelli Glenn's co-authors include Kathryn Packman, Christian Tovar, Lyubomir T. Vassilev, Nan Jiang, Qingjie Ding, Jinjun Liu, Bradford Graves, Brian Higgins, Zoran Filipovic and David Bartkovitz and has published in prestigious journals such as PLoS ONE, Neurology and Cancer Research.

In The Last Decade

Kelli Glenn

20 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

2013 447 citations Qingjie Ding, Zhuming Zhang et al. Journal of Medicinal Chemistry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kelli Glenn United States	13	895	690	182	136	126	20	1.4k
Martin Schröder Germany	21	678 0.8×	284 0.4×	142 0.8×	69 0.5×	20 0.2×	45	1.3k
Smitha Pillai United States	22	1.2k 1.3×	469 0.7×	71 0.4×	212 1.6×	82 0.7×	34	1.8k
Grégoire Prévost France	24	1.0k 1.1×	645 0.9×	181 1.0×	24 0.2×	98 0.8×	56	1.7k
Patricia A. Zipfel United States	16	596 0.7×	283 0.4×	24 0.1×	60 0.4×	72 0.6×	21	1.0k
Miljan Kuljanin United States	15	781 0.9×	257 0.4×	94 0.5×	66 0.5×	33 0.3×	30	1.1k
Gary E. Schiltz United States	18	910 1.0×	306 0.4×	265 1.5×	34 0.3×	42 0.3×	52	1.5k
George P. Amorino United States	20	778 0.9×	517 0.7×	45 0.2×	94 0.7×	118 0.9×	27	1.6k
Gargi D. Basu United States	20	793 0.9×	977 1.4×	50 0.3×	165 1.2×	27 0.2×	53	2.0k
S Krajewski United States	12	1.0k 1.2×	466 0.7×	28 0.2×	19 0.1×	105 0.8×	13	1.5k
Philip G. Kasprzyk United States	22	1.1k 1.3×	638 0.9×	299 1.6×	23 0.2×	86 0.7×	50	1.8k

Countries citing papers authored by Kelli Glenn

Since Specialization

Citations

This map shows the geographic impact of Kelli Glenn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kelli Glenn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kelli Glenn more than expected).

Fields of papers citing papers by Kelli Glenn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kelli Glenn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kelli Glenn. The network helps show where Kelli Glenn may publish in the future.

Co-authorship network of co-authors of Kelli Glenn

This figure shows the co-authorship network connecting the top 25 collaborators of Kelli Glenn. A scholar is included among the top collaborators of Kelli Glenn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kelli Glenn. Kelli Glenn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Misra, Sunita N., et al.. (2025). Potential of cenobamate as a broad-spectrum antiseizure medication. Expert Opinion on Pharmacotherapy. 26(10). 1177–1189. 1 indexed citations

Glenn, Kelli, et al.. (2023). Anticonvulsant effects of cenobamate in chemically and electrically induced seizure models in rodents. Heliyon. 9(8). e18920–e18920. 10 indexed citations

Palamanda, Jairam, et al.. (2023). Distribution, Metabolism, and Excretion of Cenobamate in Adult, Fetal, Neonatal, and Lactating Rats. European Journal of Drug Metabolism and Pharmacokinetics. 49(1). 7–21. 2 indexed citations

Greene, Stephen A., et al.. (2021). Effect of cenobamate on the single‐dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects. Clinical and Translational Science. 15(4). 899–911. 24 indexed citations

Vernillet, Laurent, et al.. (2020). Mass Balance, Metabolism, and Excretion of Cenobamate, a New Antiepileptic Drug, After a Single Oral Administration in Healthy Male Subjects. European Journal of Drug Metabolism and Pharmacokinetics. 45(4). 513–522. 26 indexed citations

Nakamura, Michiko, Chiranjivi Neupane, Byeong Hwa Jeon, et al.. (2020). Positive allosteric modulation of GABAA receptors by a novel antiepileptic drug cenobamate. European Journal of Pharmacology. 879. 173117–173117. 92 indexed citations

Glenn, Kelli, et al.. (2020). P154 - Absorption, distribution, metabolism, and excretion of the novel antiepileptic drug cenobamate: mass balance following oral administration in healthy male subjects. Drug Metabolism and Pharmacokinetics. 35(1). S69–S69. 3 indexed citations

Nakamura, Michiko, Chiranjivi Neupane, Hye‐Won Shin, et al.. (2019). Effects of Cenobamate on GABA-A Receptor Modulation (P1.5-033). Neurology. 92(15_supplement). 5 indexed citations

Quinlan, Michelle, Kelli Glenn, Hildegard Boss, et al.. (2016). Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers. British Journal of Clinical Pharmacology. 82(4). 1022–1029. 14 indexed citations

10.

Spector, Neil L., Faith C. Robertson, Sarah Bacus, et al.. (2015). Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor. PLoS ONE. 10(11). e0142845–e0142845. 21 indexed citations

11.

Glenn, Kelli, Li Yu, Micaela B. Reddy, et al.. (2015). Investigating the effect of autoinduction in cynomolgus monkeys of a novel anticancer MDM2 antagonist, idasanutlin, and relevance to humans. Xenobiotica. 46(8). 667–676. 9 indexed citations

12.

Higgins, Brian, Kelli Glenn, Antje‐Christine Walz, et al.. (2014). Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach. Clinical Cancer Research. 20(14). 3742–3752. 50 indexed citations

13.

Zhang, Zhuming, Qingjie Ding, Jinjun Liu, et al.. (2014). Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy. Bioorganic & Medicinal Chemistry. 22(15). 4001–4009. 42 indexed citations

14.

Iancu‐Rubin, Camelia, Goar Mosoyan, Kelli Glenn, et al.. (2013). Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis. Experimental Hematology. 42(2). 137–145.e5. 70 indexed citations

15.

Ding, Qingjie, Zhuming Zhang, Jinjun Liu, et al.. (2013). Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development. Journal of Medicinal Chemistry. 56(14). 5979–5983. 447 indexed citations breakdown →

16.

Chen, Yi, Zhi Chen, Romyr Dominique, et al.. (2013). Pyrido[2,3-d]pyrimidines: Discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors. Bioorganic & Medicinal Chemistry Letters. 23(24). 6610–6615. 48 indexed citations

17.

Higgins, Brian, Christian Tovar, Kelli Glenn, et al.. (2013). Abstract B55: Antitumor activity of the MDM2 antagonist RG7388.. Molecular Cancer Therapeutics. 12(11_Supplement). B55–B55. 3 indexed citations

18.

Vu, Binh Thanh, Peter M. Wovkulich, Giacomo Pizzolato, et al.. (2013). Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development. ACS Medicinal Chemistry Letters. 4(5). 466–469. 289 indexed citations

19.

Zhang, Zhuming, Xin‐Jie Chu, Jinjun Liu, et al.. (2013). Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development. ACS Medicinal Chemistry Letters. 5(2). 124–127. 68 indexed citations

20.

Luistro, Leopoldo, Wei He, Melissa Smith, et al.. (2009). Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties. Cancer Research. 69(19). 7672–7680. 154 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact